Desmoid Tumors: What Managed Care Professionals Need to Know to Manage These Unpredictable Tumors, featuring a Pharmacy Focus Podcast

Click here to access the companion podcast Challenges in Treatment of Desmoid Tumors and Managed Care Solutions.

Program Description
Desmoid tumors (DTs) are a type of nonmetastasizing, locally aggressive, fibroblastic proliferative soft-tissue sarcoma. DTs can occur at any site, but most commonly appear in the abdominal wall and/or limbs. These tumors are often unpredictable and may remain indolent for some individuals while growing excessively in others, obstructing vital structures and organs and contributing to mortality. The burden of disease in DTs includes both delays in diagnosis and misdiagnosis, which may impact treatment initiation. Recurrence after surgical resection may occur in up to 90% of patients, so systemic therapies are needed as alternatives for these patients. Recently, tyrosine kinase inhibitors (TKIs) have shown to be effective in treating progressive, unresectable DTs, and novel therapies are being investigated for DTs. This article will review evidence-based approaches and clinical data for the use of TKIs and novel therapies in the step-wise treatment of DTs, with attention to treatment decisions in individual patients. Managed care professionals should be aware of the current and emerging treatment options for DTs to inform patients and other health care providers of treatment access and approaches to reduce burden of disease.

Target audience: Managed care and oncology pharmacists
Type of activity: Application
Release date: December 1, 2023
Expiration date: February 28, 2025
Learner level: Foundational
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the presentation, prevalence, genetic etiology, pathogenesis, and prognosis for patients with desmoid tumors (DTs)
• Examine systemic treatment options used in the management of recurrent, unresectable DTs based on mechanism of action, efficacy, and risk of adverse effects
• Identify the role of an experienced, multidisciplinary DT treatment team in achieving a prompt, accurate diagnosis and avoiding inappropriate DT treatment

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-423-H01-P. The activity is available for CE credit through February 28, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Christy S. Harris, PharmD, BCOP, FHOPA, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. 

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms